Pharmacological blockade of Bcl-2, Bcl-x L and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice

Cell Death and Differentiation

Volumn 19, Issue 4, 2012, Pages 623-632

  Grabow, S ^a,b,c   Waring, P ^b   Happo, L ^a,b   Cook, M ^a   Mason, K D ^a,b   Kelly, P N ^a,b,d   Strasser, A ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Cancer Therapeutics CRC   (Australia)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

ABT 737; Bcl 2 family; cancer; lymphoma; p53

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER PREVENTION; CANCER SURVIVAL; CARCINOGENESIS; FAMILIAL CANCER; GAMMA RADIATION; GENE TARGETING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA; THYMUS LYMPHOMA; TUMOR SUPPRESSOR GENE;

ALLELES; ANIMALS; APOPTOSIS; BCL-X PROTEIN; BIOMIMETIC MATERIALS; BIPHENYL COMPOUNDS; HUMANS; LYMPHOMA; MICE; MICE, KNOCKOUT; NEOPLASMS, RADIATION-INDUCED; NEOPLASTIC SYNDROMES, HEREDITARY; NITROPHENOLS; PIPERAZINES; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES; THYMUS NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

MUS;

EID: 84858155388     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2011.133     Document Type: Article

References (34)

1. Srivastava S, Zou ZQ, Pirollo K, Plattner W, Chang EH. Germline transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-749. (Pubitemid 120015153)
2. Malkin D, Li FP, Strong LC, Fraumeni JFJ, Nelson CE, Kim DH et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233-1238. (Pubitemid 120031831)
3. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CAJ, Butel JS et al. Mice deficient for p53 are developmentally normal but are susceptible to spontaneous tumours. Nature 1992; 356: 215-221.
4. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol 1994; 4: 1-7.
5. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 2004; 119: 847-860. (Pubitemid 40017690)
6. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007; 8: 275-283. (Pubitemid 46474662)
7. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE. Cell death. N Engl J Med 2009; 361: 1570-1583.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
9. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47-59.
10. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 2004; 305: 626-629. (Pubitemid 39006738)
11. Huang DCS, Strasser A. BH3-only proteins-essential initiators of apoptotic cell death. Cell 2000; 103: 839-842.
12. Lessene G, Czabotar PE, Colman PM. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 2008; 7: 989-1000.
13. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681. (Pubitemid 40825512)
14. Park CM, Bruncko M, Adickes J, Bauch J, Ding H, Kunzer A et al. Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem 2008; 51: 6902-6915.
15. Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DC et al. In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 2008; 105: 17961-17966.
16. Cragg MS, Harris C, Strasser A, Scott CL. Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer 2009; 9: 321-326.
17. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003; 22: 8590-8607. (Pubitemid 38028528)
18. Kaplan HS, Brown MB. Further observations on inhibition of lymphoid tumor development by shielding and partial-body irradiation of mice. J Natl Cancer Inst 1951; 12: 427-436.
19. Kemp CJ, Wheldon T, Balmain A. p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nat Genet 1994; 8: 66-69.
20. Michalak EM, Vandenberg CJ, Delbridge ARD, Wu L, Scott CL, Adams JM et al. Apoptosispromoted tumorigenesis: gamma-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death. Genes Dev 2010; 24: 1608-1613.
21. Labi V, Erlacher M, Krumschnabel G, Manzl C, Tzankov A, Pinon J et al. Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation. Genes Dev 2010; 24: 1602-1607.
22. Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994; 79: 329-339.
23. Strasser A, Harris AW, Cory S. Bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 1991; 67: 889-899. (Pubitemid 121001503)
24. Motoyama N, Kimura T, Takahashi T, Watanabe T, Nakano T. bcl-x prevents apoptotic cell death of both primitive and definitive erythrocytes at the end of maturation. J Exp Med 1999; 189: 1691-1698. (Pubitemid 29272685)
25. Bouillet P, Cory S, Zhang L-C, Strasser A, Adams JM. Degenerative disorders caused by Bcl-2 deficiency are prevented by loss of its BH3-only antagonist Bim. Dev Cell 2001; 1: 645-653. (Pubitemid 33586117)
26. Print CG, Loveland KL, Gibson L, Meehan T, Stylianou A, Wreford N et al. Apoptosis regulator Bcl-w is essential for spermatogenesis but appears otherwise redundant. Proc Natl Acad Sci USA 1998; 95: 12424-12431. (Pubitemid 28483781)
27. O'Reilly LA, Print C, Hausmann G, Moriishi K, Cory S, Huang DCS et al. Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. Cell Death Differ 2001; 8: 486-494. (Pubitemid 32492769)
28. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003; 426: 671-676. (Pubitemid 38009376)
29. Opferman J, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005; 307: 1101-1104. (Pubitemid 40262114)
30. Bouillet P, Metcalf D, Huang DCS, Tarlinton DM, Kay TWH, Köntgen F et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999; 286: 1735-1738. (Pubitemid 129515880)
31. Villunger A, Michalak EM, Coultas L, Müllauer F, Böck G, Ausserlechner MJ et al. p53-and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 2003; 302: 1036-1038. (Pubitemid 37386194)
32. Cragg MS, Jansen ES, Cook M, Strasser A, Scott CL. Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest 2008; 118: 3651-3659.
33. Mandal M, Borowski C, Palomero T, Ferrando AA, Oberdoerffer P, Meng F et al. The BCL2A1 gene as a pre-T cell receptor-induced regulator of thymocyte survival. J Exp Med 2005; 201: 603-614. (Pubitemid 40289550)
34. Kaufmann T, Tai L, Ekert PG, Huang DC, Norris F, Lindemann RK et al. The BH3-only protein bid is dispensable for DNA damage-and replicative stress-induced apoptosis or cell-cycle arrest. Cell 2007; 129: 423-433. (Pubitemid 46574974)